MANF and CDNF Neurotrophic Factors for Retinal Cell Protection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for retinal degenerative disorders, such as inherited retinal disorders, age-related macular degeneration, and glaucoma, lack effective methods to rescue photoreceptors and retinal ganglion cells, leading to progressive cell degeneration and vision loss.
Innovation Solution
Administration of neurotrophic factors, specifically Mesencephalic astrocyte-derived neurotrophic factor (MANF) and conserved dopamine neurotrophic factor (CDNF), either individually or in combination, to promote the survival and protection of photoreceptors and retinal ganglion cells through intravitreal injection or sustained-release vehicles, targeting the eye to inhibit degeneration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for retinal degenerative disorders are used, then existing therapeutic approaches are maintained, but photoreceptors and retinal ganglion cells continue to degenerate progressively leading to vision loss
Solution Approach 1:
The patent introduces MANF and CDNF as intermediary neurotrophic factors that mediate protection between the administered substance and the retinal cells. These factors act as biological mediators that bind to retinal cells and trigger survival signaling pathways, preventing direct harmful effects of degenerative processes on photoreceptors and ganglion cells.
Solution Approach 2:
The patent utilizes the endogenous neurotrophic capabilities of MANF and CDNF to enable retinal cells to protect themselves. By administering these factors, the treatment activates the cells' intrinsic survival mechanisms and protective pathways, allowing the cells to self-protect against degeneration rather than relying solely on external replacement therapies.
2Reliability
If neurotrophic factors MANF and CDNF are administered to rescue photoreceptors and retinal ganglion cells, then cell survival and protection are promoted, but the complexity of treatment administration increases
Solution Approach 1:
The patent employs MANF and CDNF as universal neurotrophic factors that can protect multiple types of retinal cells (photoreceptors, ganglion cells, and other neuronal cells) through a single administration. These factors exhibit multi-functional protective effects across different cell types and degenerative conditions, reducing the need for cell-specific targeted therapies and simplifying the overall treatment approach.
3Duration of action of stationary object
If sustained-release vehicles are used for neurotrophic factor administration, then duration of therapeutic effect is extended, but device complexity and manufacturing difficulty increase
Solution Approach 1:
The patent utilizes parameter changes in the formulation of sustained-release vehicles, such as adjusting polymer composition, molecular weight, crosslinking density, or degradation rates, to control the release kinetics of neurotrophic factors. By modifying these physical and chemical parameters, the treatment duration and release profile can be optimized without fundamentally changing the administration device structure, thereby balancing extended duration with manufacturing feasibility.
Data Source
AI summary
The present invention provides methods of treating a retinal disorder comprising administering an effective amount of a neurotrophic factor to a subject having the retinal disorder. The neurotrophic factors useful in the invention include mesencephalic astrocyte-derived neurotrophic factor (MANF) and conserved dopamine neurotrophic factor (CDNF). The present invention further comprises pharmaceutical compositions and kits containing MANF and CDNF.